ViiV Healthcare

From Wikipedia, the free encyclopedia
Jump to: navigation, search
ViiV Healthcare
Type Joint venture
Industry Healthcare
Founded November 2009 (2009-11)
Headquarters Brentford, Greater London, UK
Area served Global
Key people Dominique Limet, (CEO)
Products Pharmaceuticals
Parent
Website Official website

ViiV Healthcare is a pharmaceutical company specialising in the development of therapies for HIV that was created as a joint venture by Pfizer and GlaxoSmithKline in November 2009 with both companies transferring their HIV assets to the new company.[1] In 2012 Shionogi joined the company. 76.5% of the company is now owned by GlaxoSmithKline, 13.5% by Pfizer and 10% by Shionogi.[2] This ownership structure may change depending upon the achievement of certain milestones.[1]

ViiV Healthcare's products have a market share of approximately 19 percent[3] of the global HIV market, which makes it the second largest health care company, following after Gilead Sciences, that is working on the treatment of HIV.[4]

ViiV Healthcare's headquarters are in Brentford in the United Kingdom and it has sites in a number of other countries including; the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[5]

Products[edit]

The company currently markets 11 products:[6][7]

Treatment access programs[edit]

ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low and middle income countries, as well as all of Sub-Saharan Africa.[8]

The company has also granted voluntary licenses to 14 generics companies to enable the low cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.[9][10]

Criticisms[edit]

The foundation of ViiV Healthcare has been criticised by Treatment Action Group which had suspicions about the motives behind Pfizer and GlaxoSmithKline's desire to form the new company. The group's concerns centred on the possibility that the two pharmaceutical companies were using ViiV Healthcare as a way to get out of a field of research that has not been particularly commercially successful.[1]

See also[edit]

References[edit]

  1. ^ a b c Jacks, Andrew "GSK and Pfizer to merge HIV portfolios Financial Times. 16 April 2010
  2. ^ "Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio". viivhealthcare.com. Retrieved 2014-03-07. 
  3. ^ "ViiV company website – about us" Accessed 13 October 2010
  4. ^ Jacks, Andrew "ViiV vows joint venture will help fight HIV" Financial Times. 3 November 2009
  5. ^ "ViiV company website – about us" Accessed 13 October 2010
  6. ^ "ViiV company website – products" Accessed 13 October 2010
  7. ^ McNeil, Donald "AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease" New York Times. 9 November 2009
  8. ^ "ViiV company website – access to medicines" Accessed 12 January 2014
  9. ^ "ViiV company website – access to medicines" Accessed 12 January 2014
  10. ^ Reuters "Glaxo, Pfizer JV opens HIV pipeline to generic companies" Africa – the good news, 19 July 2010